medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2018, Number 3

<< Back Next >>

Rev Mex Periodontol 2018; 9 (3)

Paraneoplastic pemphigus. A case report

Padilla RM, Nava VM, Godínez RJM, Puebla MAG, Zepeda NJS

Language: Spanish
References: 30
Page: 50-54
PDF size: 363.68 Kb.


ABSTRACT

Paraneoplastic pemphigus (PNP) is a fatal autoimmune bullous disease associated with an underlying malignancy. PNP occurs most frequently between 45 and 70 years. A wide variety of lesions that include the oral mucosa and the skin have been described. There is a spectrum of at least five clinical variants with different morphology. Similarly, the histological findings are very variable. Investigations to diagnose PNP should include histopathological study, immunofluorescence, the search for tumors and immunological studies in serum. The treatment of PNP is difficult and the best results have been reported with benign neoplasms that have been surgically removed. The first-line treatment is the administration of high doses of corticosteroids with the addition of steroid-sparing agents. Treatment failures are often treated with rituximab with or without concomitant intravenous immunoglobulin. In general, the prognosis is bad. In this article we report a clinical case of a female with a history of vesicular-erosive lesions in the gum and soft palate, with a history of breast cancer in remission; post-biopsy and histopathological result multiple active metastatic lesions were identified.


REFERENCES

  1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012; 45 (1): 7-35.

  2. Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmunity Reviews. 2014; 13: 482-489.

  3. Kartan S, Shi V, Clark A, Chan L. Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment. Am J Clin Dermal. 2017; 18: 105-126.

  4. DiMarco C. Pemphigus: Pathogenesis to treatment. R I Med J. 2016; 99 (12): 28-31.

  5. Giannetti L, Generali L, Bartoldi C. Oral pemphigus. G Ital Dermatol Venereol. 2018; doi: 10.23736/S0392-0488.18.05887-X.

  6. Zimmermann J, Bahmer F, Rose C, Zillikens D, Schidt E. Clinical and inmunopathologgical spectrum of paraneoplastic pemphigus. J Dtsh Dermatol Ges. 2010; 8: 598-606.

  7. Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR et al. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. Int J Mol Sci. 2017; 18: 2532; doi: 10.3390/ijms18122532.

  8. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004; 40: 553.

  9. Ohzono A, Sogame R, Li X et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015; 173: 1447.

  10. Khalaf Kridin. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunologic Research. 2018; 66 (2): 255-270.

  11. Ghada AZ, Micheletti R, Nasta SD, Palakshappa J, Stoopler ET. The importance of multidisciplinary healthcare for paraneoplastic pemphigus. Spec Care Dentist. 2015; 35 (3): 143-147.

  12. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004; 9: 29-33.

  13. Melnick LE, Beasley JM, Kim R, Brinster N, Sicco KL. Paraneoplastic pemphigus in a 34-year-old. Dermatol Online J. 2017; 23: pii: 13030/qt8sf4c5xn. PMID: 29447659

  14. Gambino A, Carbone M, Arduino PG, Carcieri P, Carbone L, Broccoletti R. Conservative approach in patients with pemphigus gingival vulgaris: A pilot study of five cases. Int J Dent. 2014. 2014; 747506.

  15. Ohta M, Osawa S, Endo H, Kuyama K, Yamamoto H, Ito T. Pemphigus vulgaris confined to the gingiva: A case report. Int J Dent. 2011; 207153.

  16. Brystryn JC, Rudolph JL. Pemphigus. Lancet. 2005; 366: 61-73.

  17. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M et al. Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323: 1729-1735.

  18. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol. 1999; 40: 649-671.

  19. Kneisel A, Hertl M. Autoinmmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges. 2011; 9: 844-856.

  20. Rivollier C, Vaillant L, Machet MC, Martin L, Jan V, Huttenberger B et al. Paraneoplastic pemphigus: a pustular from during chronic lymphoid leukemia. Ann Dermatol Venereol. 2011; 128: 644-649.

  21. Wang J, Zhu X, Li R, Tu P, Wang R, Zhang L et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. 2005; 141: 1285-1293.

  22. Fang Y, Zhao L, Yan F, Cui X, Xia Y, Duren A et al. A critical role of 
surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman’s disease. Med Oncol. 2010; 27: 907.

  23. Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009; 48: 162.

  24. Hertzberg MS, Schifter M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin’s lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol. 2000; 63: 105.

  25. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001; 66: 142-144.

  26. Brown AE, Montaparthi K, Hsu S. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Dermatol Online J. 2018; 12: pii: 13030/qt96v387cj. PMID: 29447653.

  27. Anan T, Shimizu F, Hatano Y, Okamoto O, Katagiri K, Fujiwara S. Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: a case report and review of cases treated with rituximab. J Dermatol. 2011; 38: 1084.

  28. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007; 34: 503.

  29. Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012; 148: 1165-1172.

  30. Kridin K, Zelber-Sagi S, Bergman R. Mortality and cause of death in patients with pemphigus. Acta Derm Venereol. 2017; 97: 607-611.




2020     |     www.medigraphic.com